ADJUSTMENT OF BLOOD-SUGAR LEVELS WITH INSULIN AND GLUCAGON EYEDROPS IN NORMAL AND DIABETIC RABBITS

被引：14

作者：

CHIOU, GCY

SHEN, ZF

ZHENG, YQ

机构：

[1] Institute of Ocular Pharmacology, Department of Medical Pharmacology and Toxicology, Texas A&M University College of Medicine, College Station, TX

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1990年 / 6卷 / 03期

关键词：

D O I：

10.1089/jop.1990.6.233

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The ophthalmic solutions of insulin and glucagon plus permeation enhancers, BL-9 and Brij-78, were administered to rabbit eyes to study the systemic absorption of these peptide drugs and their effects to affect the blood glucose levels. When plain insulin eyedrops were given, the blood sugar levels were little affected. When insulin plus permeation enhancers were instilled to the eyes, the blood glucose reduced markedly in both normal and diabetic animals. Although sufficient concentrations of glucagon can be reached with plain glucagon eyedrops, the addition of permeation enhancers increased the systemic absorption of glucagon through eyes markedly. As a result, the blood sugar levels were raised markedly by glucagon eyedrops at much lower concentrations. These results indicate that systemic delivery of insulin, glucagon, and other peptide drugs through eyes is a feasible alternative route to parenteral injection particularly when permeation enhancers are added. © 1990, Mary Ann Liebert, Inc. All rights reserved.

引用

页码：233 / 241

页数：9

共 15 条

[1]

Yamasaki Y., Shichiri M., Kawamori R., Kikkuchi M., Yagi T., Arai S., Tohdo R., Hakui N., 0ji N., Abe H., The effectiveness of rectal administration of insulin suppository on normal and diabetic subjects, Diabetes Care, 4, pp. 454-458, (1981)

[2]

Fisher N.F., The absorption of insulin from the intestine, vagina and scrota sac, Am. J. Physiol, 67, pp. 65-71, (1923)

[3]

Anders R., Merkle H.P., Schurr W., Ziegler R., Buccal absorption of protirelin: An effective way to stimulate thyrotropin and prolactin, J. Pharm. Sci, 72, pp. 1481-1483, (1983)

[4]

Moses A.C., Gordon G.S., Carey M.S., Flier J.S., Insulin administered intranasally as an insulin-bile salt aerosol, effectiveness and reproducibility in normal and diabetic subjects, Diabetes, 32, pp. 1040-1047, (1983)

[5]

Hirai S., Ikenaga T., Matsuzawa T., Nasal absorption of insulin in dogs, Diabetes, 27, pp. 296-299, (1978)

[6]

Salzman R., Manson J.E., Griffing G.T., Kimmerle R., Ruderman N., Phil D., McCall A., Stoltz E.I., Mullin C., Smaal D., Armstrong J., Melby J.C., Intranasal aerosolized insulin

[7]

mixed-meal studies and long-term use in type I diabetes, New England J. Med, 312, pp. 1078-1084, (1985)

[8]

Wigley F.M., Londono J.H., Wood S.H., Shipp J.C., Waldman R.H., Insulin across respiratory mucosae by aerosol delivery, Diabetes, 20, pp. 552-556, (1971)

[9]

Chiou G.C.Y., Chuang C.Y., Systemic delivery of polypeptides with molecular weights of between 300 and 3500 through the eyes, J. Ocular Pharmacol, 4, pp. 165-177, (1988)

[10]

Chiou G.C.Y., Chuang C.Y., Treatment of hypoglycemia with glucagon eyedrops, J. Ocular Pharmacol, 4, pp. 179-186, (1988)

← 1 2 →